Study on the expression of various mediators and CINV during moderately emetogenic risk chemotherapy.

2022 Fiscal Year Final Research Report

• Project/Area Number: 17K09312
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: General internal medicine(including psychosomatic medicine)
• Research Institution: Sapporo Medical University
• Principal Investigator: Okita Kenji 札幌医科大学, 医学部, 助教 (70517911)
• Co-Investigator(Kenkyū-buntansha): 植木 知身 札幌医科大学, 医学部, 助教 (00516627) ; 九冨 五郎 札幌医科大学, 医学部, 講師 (10404625) ; 竹政 伊知朗 札幌医科大学, 医学部, 教授 (50379252) ; 西舘 敏彦 札幌医科大学, 医学部, 助教 (80404606)
• Project Period (FY): 2017-04-01 – 2023-03-31
• Keywords: CINV / NK1RA / MEC

Outline of Final Research Achievements

As the Clinical Research Act came into force during the study period, the study had to be applied for as a specific clinical study in order to carry out the study as originally planned, but application was difficult and the study plan had to be changed. In addition, the study was temporarily suspended due to the COVID-19 pandemic during the study period, and changes in the chemotherapy regimen being carried out at the department meant that blood data could only be obtained for 10 patients, and the original aim could not be completed. However, the results of the CINV study were used for a conference presentation on individualised treatment. They also assisted the then ongoing research on steroid reduction for moderate emetogenic risk.

Free Research Field

化学療法

Academic Significance and Societal Importance of the Research Achievements

現在、中等度催吐性リスク抗がん薬におけるCINV予防に関するトピックとしては、オランザピンの適応の必要性や、超遅発期CINVの実態把握やそれに対する予防療法の確立である。本研究は予定した研究を完遂できず目的は達成できなかったが、CINVに対する個別予防を研究するという研究ストラテジーは、上記の現在における制吐療法の問題点においても適応可能であると考えられる。